SAT-091 Metabolic Effects of JAK1/2 Inhibition in Patients with Myeloproliferative Neoplasms

Background: Ruxolitinib is a JAK1/2 inhibitor that is FDA approved to treat certain myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). The JAK family kinases are targeted in cancers due to their role in cytokine receptor signal transduction, and are also ke...

Descripción completa

Detalles Bibliográficos
Autores principales: Sapre, Manali, Tremblay, Douglas, Leiter, Amanda, Coltoff, Alexander, Geevarghese, Anita, Mascarhenas, John, Gallagher, Emily
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrine Society 2019
Materias:
Adipose Tissue, Appetite, and Obesity
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552330/
http://dx.doi.org/10.1210/js.2019-SAT-091

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552330/
http://dx.doi.org/10.1210/js.2019-SAT-091

Ejemplares similares